N
NMRA
Neumora Therapeutics Inc
0.7785
+0.0867+12.53%After Hours: 0.8100 +0.0315 +4.05%19:59 09/22 EDT
OPEN/PREV CLOSE0.4647/0.4710
TODAY RANGE0.4514-0.4819
VOL2.76M
MARKET CAP87.99M
52 WEEK RANGE0.4514-3.650
AVG VOL (3M)1.18M
% TURNOVER1.44%
TURNOVER0
P/E (TTM)-0.3797
% RANGE6.37%
EPS(TTM)-1.2333
P/E(FORWARD)-0.5352
P/B1.965
BVPS0.2383
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP66.52M
SHARES OUTSTANDING187.90M
NEXT EARNINGS--
FREE FLOAT142.05M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·08/29 12:00
Insiders Sold Neumora Therapeutics Prematurely At US$2.29 With Stock Trading Higher
TipRanks·08/22 02:05
Top Neumora Executive Makes Notable Move With Insider Stock Sale
TipRanks·08/18 02:25
Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital
TipRanks·08/17 15:50
Neumora CEO transition not a surprise, says H.C. Wainwright
TipRanks·08/16 13:42
Neumora Therapeutics CEO Paul Berns to switch roles, Joshua Pinto to succeed
TipRanks·08/14 16:35
Neumora Therapeutics, Inc. (NMRA) Receives a Rating Update from a Top Analyst
NASDAQ·08/14 13:46
Neumora Q2 Loss Narrows, Advances CNS Pipeline; Names Joshua Pinto CEO
TipRanks·08/14 11:28
Neumora Therapeutics Announces CEO Transition and Q2 Results
Dow Jones·08/14 11:26
Neumora Therapeutics Promotes Pinto to CEO
Seeking Alpha·08/14 11:09
Neumora Therapeutics GAAP EPS of -$0.23 beats by $0.01
Dow Jones·08/14 11:02
*Neumora Therapeutics: Co-founder Paul L. Berns Will Serve as Executive Chair
Dow Jones·08/14 11:01
*Neumora Therapeutics Names Joshua Pinto Pres and CEO
Dow Jones·08/14 11:00
Press Release: Neumora Therapeutics Reports -2-
Seeking Alpha·07/31 18:09
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline
Same Industry
Name/Symbol
Change%
Price